Serum glycoprotein non-metastatic melanoma protein B (GPNMB) level as a potential biomarker for diabetes mellitus-related cataract: A cross-sectional study
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Serum glycoprotein non-metastatic melanoma protein B (GPNMB) level as a potential biomarker for diabetes mellitus-related cataract: A cross-sectional study
Authors
Keywords
-
Journal
Frontiers in Endocrinology
Volume 14, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2023-02-16
DOI
10.3389/fendo.2023.1110337
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Type 2 diabetes mellitus-associated cognitive dysfunction: Advances in potential mechanisms and therapies
- (2022) Ailin Luo et al. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
- Downregulation of glycoprotein non-metastatic melanoma protein B prevents high glucose-induced angiogenesis in diabetic retinopathy
- (2022) Tingyu Qin et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- GPNMB confers risk for Parkinson’s disease through interaction with α-synuclein
- (2022) Maria E. Diaz-Ortiz et al. SCIENCE
- IDF diabetes Atlas: Global estimates of undiagnosed diabetes in adults for 2021
- (2021) Katherine Ogurtsova et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- GPNMB plays a protective role against obesity-related metabolic disorders by reducing macrophage inflammatory capacity
- (2021) Adam Prabata et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Mortality attributable to diabetes in 20–79 years old adults, 2019 estimates: Results from the International Diabetes Federation Diabetes Atlas, 9th edition
- (2020) Pouya Saeedi et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Urinary Sediment Transcriptomic and Longitudinal Data to Investigate Renal Function Decline in Type 1 Diabetes
- (2020) Maria Beatriz Monteiro et al. Frontiers in Endocrinology
- Acute Kidney Injury: A Bona Fide Complication of Diabetes
- (2020) Andrew Advani DIABETES
- Osteoactivin inhibits dexamethasone-induced osteoporosis through up-regulating integrin β1 and activate ERK pathway
- (2018) He Hu et al. BIOMEDICINE & PHARMACOTHERAPY
- A systematic review of risk factors for cataract in type 2 diabetes
- (2018) Jocelyn J. Drinkwater et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Inflammatory mechanisms linking obesity and metabolic disease
- (2017) Alan R. Saltiel et al. JOURNAL OF CLINICAL INVESTIGATION
- Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic Medications
- (2015) CA Alvarez et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Expression and immunolocalization of Gpnmb, a glioma-associated glycoprotein, in normal and inflamed central nervous systems of adult rats
- (2012) Jian-Jun Huang et al. Brain and Behavior
- Global estimates of visual impairment: 2010
- (2011) Donatella Pascolini et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Glycoprotein nonmetastatic melanoma protein b, a melanocytic cell marker, is a melanosome-specific and proteolytically released protein
- (2010) Toshihiko Hoashi et al. FASEB JOURNAL
- ADAM10 Releases a Soluble Form of the GPNMB/Osteoactivin Extracellular Domain with Angiogenic Properties
- (2010) April A. N. Rose et al. PLoS One
- Gpnmb is a melanosome-associated glycoprotein that contributes to melanocyte/keratinocyte adhesion in a RGD-dependent fashion
- (2009) Mizuki Tomihari et al. EXPERIMENTAL DERMATOLOGY
- Osteoactivin, an anabolic factor that regulates osteoblast differentiation and function
- (2008) S ABDELMAGID et al. EXPERIMENTAL CELL RESEARCH
- Involvement of PI3K/Akt Pathway in TGF-β2-Mediated Epithelial Mesenchymal Transition in Human Lens Epithelial Cells
- (2008) Ke Yao et al. OPHTHALMIC RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More